Centessa rises on FDA's 'orphan drug' tag for hemophilia drug

Centessa Pharmaceuticals

14/09/2022 17:03

** U.S.-listed shares of Centessa Pharmaceuticals PLC
 CNTA.O  up ~1% at $4.30 - on track for third straight session
of gains this week 
    ** UK-based biotech says U.S. Food and Drug Administration
granted "orphan drug" designation to its drug, SerpinPC, for
treatment of hemophilia  urn:newsml:reuters.com:*:nGNE25bjLj 
    ** Hemophilia is a bleeding disorder in which blood does not
clot properly
    ** Co says data from mid-stage open label study of SerpinPC
expected in Q4 2022
    ** U.S. health regulator's orphan drug status is given to
drugs which treat rare conditions and are protected through a
series of government incentives after launch
    ** As of last close, stock down ~62% YTD 

 (Reporting by Bhanvi Satija in Bengaluru)
 ((Bhanvi.Satija@thomsonreuters.com; Outside U.S. +91
9873062788;))